Advances and challenges in circulating tumor DNA-based early detection of lung cancer
Open Access
- 1 October 2025
- journal article
- Published by AME Publishing Company in Translational Cancer Research
- Vol. 14 (10) , 7428-7437
Abstract
Lung cancer remains the leading cause of cancer-related mortality worldwide. The primary reason for this poor prognosis is late-stage diagnosis, as approximately 50% of lung cancer cases are detected at stage 4 when curative treatment is no longer an option, and the 5-year survival of this stage is approximately 15%. While low-dose computed tomography (LDCT) has significantly improved early detection, its high false-positive rate (60–70%) leads to unnecessary invasive procedures and patient anxiety. Therefore, a complementary, highly specific, and non-invasive biomarker is urgently needed. Liquid biopsy, particularly circulating tumor DNA (ctDNA) analysis, has emerged as a promising diagnostic tool for lung cancer screening. Unlike conventional tissue biopsies, ctDNA-based tests provide a minimally invasive means to detect cancer-specific genomic alterations, including somatic mutations, DNA methylation patterns, somatic copy number alterations (CNAs), and fragment size variations. While ctDNA analysis has demonstrated clinical utility in advanced lung cancer, its application in early-stage disease remains challenging due to the low abundance of ctDNA in circulation. Strategies such as whole-genome methylation profiling, CNA analysis, and fragmentomics have been explored to enhance sensitivity and specificity for early detection. This review summarizes recent advances and challenges in ctDNA-based lung cancer screening, focusing on the strengths and limitations of different approaches. We highlight the need for integrating ctDNA assays with current LDCT screening protocols to improve diagnostic accuracy. Future large-scale prospective studies are essential to validate the clinical utility of ctDNA-based liquid biopsy in early lung cancer detection. A multi-modal biomarker strategy that combines genetic, epigenetic, and structural features holds great promise for transforming lung cancer screening and improving clinical outcomes.Keywords
This publication has 58 references indexed in Scilit:
- ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS StudyJournal of Thoracic Oncology, 2016
- Inferring expressed genes by whole-genome sequencing of plasma DNANature Genetics, 2016
- Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromesBlood, 2015
- Trends in the Proportion of Patients With Lung Cancer Meeting Screening CriteriaJAMA, 2015
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human MalignanciesScience Translational Medicine, 2014
- Probability of Cancer in Pulmonary Nodules Detected on First Screening CTNew England Journal of Medicine, 2013
- Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNANature, 2013
- Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencingGenome Medicine, 2013
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningNew England Journal of Medicine, 2011
- Validation of a DNA methylation microarray for 450,000 CpG sites in the human genomeEpigenetics, 2011